Y Wang1, Y Li2, L Xia1, K Niu1, X Chen3, D Lu3, R Kong1, Z Chen4, J Sun5. 1. Department of Oncology, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China. 2. Department of Gastroenterology, First People's Hospital of Liangjiang New District, Chongqing, 400020, China. 3. Medical English Department, College of Basic Medicine, Third Military Medical University, Chongqing, 400038, China. 4. Department of Oncology, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China. czt05@163.com. 5. Department of Oncology, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China. sunjg09@aliyun.com.
Abstract
BACKGROUND: Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is the optimal treatment for EGFR-mutant advanced non-small cell lung cancer (NSCLC). However, most patients developed systemic or local progression due to acquired EGFR-TKI resistance. This retrospective study aimed to evaluate the feasibility of continued EGFR-TKI with concurrent radiotherapy (CTCRT) in patients with local progression after front-line EGFR-TKI treatment. METHODS: Advanced NSCLC patients with active EGFR mutation who received EGFR-TKI were treated with CTCRT after local progression. Medical data were analyzed for time to progression (TTP), progression-free survival (PFS), tumor response rate, overall survival (OS) and adverse events. RESULTS: A total of 50 irradiated lesions from 44 patients were included. Median TTP and PFS of measurable lesions (n = 31) were both significantly prolonged after local radiotherapy (TTP1 + TTP2 vs. TTP1: 21.7 vs. 16.0 months, P = 0.010; PFS1 + PFS2 vs. PFS1: 21.3 vs. 16.0 months, P = 0.027). For all lesions (n = 50), objective response rate (ORR) and local tumor control rate (LCR) were 54.0 and 84.0%, respectively. Median OS was 26.6 months. There were no serious adverse events before or after radiotherapy. CONCLUSIONS: The treatment modality of CTCRT is considerable and effective for EGFR-mutant NSCLC patients even with local failure from front-line EGFR-TKI treatment.
BACKGROUND: Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is the optimal treatment for EGFR-mutant advanced non-small cell lung cancer (NSCLC). However, most patients developed systemic or local progression due to acquired EGFR-TKI resistance. This retrospective study aimed to evaluate the feasibility of continued EGFR-TKI with concurrent radiotherapy (CTCRT) in patients with local progression after front-line EGFR-TKI treatment. METHODS: Advanced NSCLCpatients with active EGFR mutation who received EGFR-TKI were treated with CTCRT after local progression. Medical data were analyzed for time to progression (TTP), progression-free survival (PFS), tumor response rate, overall survival (OS) and adverse events. RESULTS: A total of 50 irradiated lesions from 44 patients were included. Median TTP and PFS of measurable lesions (n = 31) were both significantly prolonged after local radiotherapy (TTP1 + TTP2 vs. TTP1: 21.7 vs. 16.0 months, P = 0.010; PFS1 + PFS2 vs. PFS1: 21.3 vs. 16.0 months, P = 0.027). For all lesions (n = 50), objective response rate (ORR) and local tumor control rate (LCR) were 54.0 and 84.0%, respectively. Median OS was 26.6 months. There were no serious adverse events before or after radiotherapy. CONCLUSIONS: The treatment modality of CTCRT is considerable and effective for EGFR-mutant NSCLCpatients even with local failure from front-line EGFR-TKI treatment.
Entities:
Keywords:
Advanced NSCLC; Continued EGFR-TKI; EGFR active mutation; Local progression; Radiation therapy
Authors: Puneeth Iyengar; Brian D Kavanagh; Zabi Wardak; Irma Smith; Chul Ahn; David E Gerber; Jonathan Dowell; Randall Hughes; Ramzi Abdulrahman; D Ross Camidge; Laurie E Gaspar; Robert C Doebele; Paul A Bunn; Hak Choy; Robert Timmerman Journal: J Clin Oncol Date: 2014-10-27 Impact factor: 44.544
Authors: Andrew J Weickhardt; Benjamin Scheier; Joseph Malachy Burke; Gregory Gan; Xian Lu; Paul A Bunn; Dara L Aisner; Laurie E Gaspar; Brian D Kavanagh; Robert C Doebele; D Ross Camidge Journal: J Thorac Oncol Date: 2012-12 Impact factor: 15.609
Authors: Helena A Yu; Camelia S Sima; James Huang; Stephen B Solomon; Andreas Rimner; Paul Paik; M Catherine Pietanza; Christopher G Azzoli; Naiyer A Rizvi; Lee M Krug; Vincent A Miller; Mark G Kris; Gregory J Riely Journal: J Thorac Oncol Date: 2013-03 Impact factor: 15.609
Authors: Amit K Das; Benjamin P Chen; Michael D Story; Mitsuo Sato; John D Minna; David J Chen; Chaitanya S Nirodi Journal: Cancer Res Date: 2007-06-01 Impact factor: 12.701
Authors: Mizuki Nishino; Junwei Lu; Takuya Hino; Natalie I Vokes; Pasi A Jänne; Hiroto Hatabu; Bruce E Johnson Journal: J Thorac Imaging Date: 2021-09-15 Impact factor: 3.000